shot-button
Ganesh Chaturthi Ganesh Chaturthi
Home > News > World News > Article > US FDA adds warning on Johnson Johnson vaccine related to rare neurological disorder

US FDA adds warning on Johnson & Johnson vaccine related to rare neurological disorder

Updated on: 13 July,2021 12:00 AM IST  |  Washington
IANS |

Guillain Barre syndrome is a neurological disorder in which the body's immune system damages nerve cells, causing muscle weakness and sometimes paralysis, Xinhua news agency reported citing the FDA as saying.

US FDA adds warning on Johnson & Johnson vaccine related to rare neurological disorder

A man shows a vial of the US Johnson and Johnson vaccine. Pic/AFP

The US Food and Drug Administration (FDA) added a new warning on the Johnson & Johnson Covid-19 vaccine, saying the jabhas been linked to a serious but rare side effect called Guillain-Barre syndrome.


Guillain Barre syndrome is a neurological disorder in which the body's immune system damages nerve cells, causing muscle weakness and sometimes paralysis, Xinhua news agency reported citing the FDA as saying.



The syndrome has occurred in some people who have received the Johnson & Johnson vaccine, the FDA in a letter on Monday.


In most of these people, symptoms began within 42 days following injections of the vaccine, it added.

The chance of having this occur is very low, the agency said.

About 100 preliminary reports of Guillain-Barre syndrome have been detected in vaccine recipients after the administration of 12.8 million doses of the Johnson & Johnson jab in the US, The Washington Post quoted the Centers for Disease Control and Prevention (CDC) as saying in a statement.

Of these reports, 95 were serious and required hospitalization, and one had dead.

The cases have largely been reported about two weeks after vaccination and mostly in men, many aged 50 and older, according to the CDC.

Johnson & Johnson said on Monday it has been in discussions with the FDA and other regulators about rare cases of Guillain-Barre syndrome.

The chance of having this occur is very low, and the rate of reported cases exceeds the background rate by a small degree, the company said in a statement.

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever.

"Exciting news! Mid-day is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest news!" Click here!


Mid-Day Web Stories

Mid-Day Web Stories

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK